Multiparticulate technology is seeing increasing use in the pharmaceutical industry to enable modified release, high dose, and age-appropriate dosage forms. Familiarity with key concepts in technology selection, development, scale up and commercialization paths available for multiparticulate intermediates can be a barrier when deciding whether a multiparticulate approach might be enabling for your compound. This webinar is aimed at guiding formulators and CMC leads on decision criteria for selecting or excluding a multiparticulate approach in early phase development. Formulation and process selection will be discussed for key application areas of this technology, with a forward-looking view on the commercialization paths available. After watching this webinar, viewers will have a working knowledge of multiparticulate technology selection, development, and scale up paths, and commercial manufacturing options for this important class of pharmaceutical dosage forms. In particular, Lonza’s commercial melt-spray-congeal, fluid bed coating, and encapsulation technologies will be highlighted.

Key Learning Objectives

  •  Understand decision criteria in technology selection for multiparticulates – where it can help, and where it won’t.
  • Develop a working knowledge of development and scale-up concepts for multiparticulate intermediates.
  • Understand the commercialization options available for key application areas.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center